Abstract
Objective: This study aimed to examine whether 1-month BMI improvement is predictive of superior 6- and 12-month BMI changes in a national sample of youth in pediatric weight management treatment. Methods: Participants were 4- to 18-year-olds from the Pediatric Obesity Weight Evaluation Registry, a prospective study collecting data from 31 pediatric weight management programs across the United States. Response at 1 month was defined as ≥ 3% BMI reduction; success at 6 and 12 months was defined as ≥ 5% BMI reduction from baseline. Analyses used linear and logistic regression with robust variance estimation. Results: Primary analyses were completed with 687 participants (mean age 12.2 years). One-month responders demonstrated significant improvements in BMI compared with nonresponders at 6 months (BMI, −2.05 vs. 0.05; %BMI, −5.81 vs. 0.23; P < 0.001 for all) and 12 months (BMI, −1.87 vs. 0.30; %BMI, −5.04 vs. 1.06; P < 0.001 for all). The odds of success for 1-month responders were 9.64 (95% CI: 5.85-15.87; P < 0.001) times that of nonresponders at 6 months and 5.24 (95% CI: 2.49-11.02; P < 0.001) times that of nonresponders at 12 months. Conclusions: In treatment-seeking youth with obesity, early BMI reduction was significantly associated with greater long-term BMI reduction. Nonresponders may benefit from early treatment redirection or intensification.
Original language | English (US) |
---|---|
Pages (from-to) | 272-279 |
Number of pages | 8 |
Journal | Obesity |
Volume | 27 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2019 |
Funding
Funding agencies: This work was supported in part by National Center for Advancing Translational Sciences award UL1TR002494. The Be Forever Fit Program at Harbor-UCLA Medical Center and the Energy Management for Personalized Weight Reduction (EMPOWER) clinic at Children’s Hospital Los Angeles receive support from UniHealth Foundation to support their participation in Pediatric Obesity Weight Evaluation Registry (POWER). Disclosure: ASK receives research support (drug/placebo) from Astra Zeneca Pharmaceuticals and serves as a consultant for Novo Nordisk, Orexigen, and Vivus Pharmaceuticals but does not accept personal or professional income for these activities. JRR receives research support in the form of drug/placebo from Boehringer Ingelheim. CKF receives research support from Novo Nordisk. ACG, AMK, CRB, MS, JMT, and JKY have no conflicts of interest to disclose. Author contributions: ACG conceptualized and designed the study, coordinated manuscript writing, drafted portions of the manuscript, and reviewed and revised the manuscript; ASK and JRR conceptualized and designed the study and reviewed and revised the manuscript; AMK and KDR conducted statistical analyses, drafted portions of the manuscript, and reviewed and revised the manuscript; CRB, MS, JMT, and CKF conceptualized and designed the study, collected data at study sites, and reviewed and revised the manuscript; JKY conceptualized and designed the study, collected data, drafted portions of the manuscript, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. Clinical trial registration: ClinicalTrials.gov identifier NCT02121132. Received: 29 August 2018; Accepted: 17 October 2018; Published online 24 January 2019. doi:10.1002/oby.22367 agencies: This work was supported in part by National Center for Advancing Translational Sciences award UL1TR002494. The Be Forever Fit Program at Harbor-UCLA Medical Center and the Energy Management for Personalized Weight Reduction (EMPOWER) clinic at Children’s Hospital Los Angeles receive support from UniHealth Foundation to support their participation in Pediatric Obesity Weight Evaluation Registry (POWER).
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Nutrition and Dietetics